Rybelsus®

Semaglutide

Rybelsus® tablets (semaglutide) is a prescription medicine used in adults with type 2 diabetes mellitus to decrease blood sugar levels. Rybelsus® can be prescribed when other diabetes medicines have been tried without success and should be used together with diet and exercise. Rybelsus® tablets work to lower blood sugar (glucose) levels by increasing how much insulin is released and decreasing glucagon secretion. This medicine also may slow gastric emptying after eating.
more
Package Per pill Price Savings Order
90 tablet
Free AirMail shipping Hot
Rs 4493.53
Rs 404417.35Rs 4493.53
Rs 53894.35
60 tablet
Free AirMail shipping Hot
Rs 4793.02
Rs 287581.34Rs 4793.02
Rs 17959.79
30 tablet
Free AirMail shipping Hot
Rs 5092.35
Rs 152770.57Rs 5092.35
Package Per pill Price Savings Order
90 tablet
Free AirMail shipping Hot
Rs 5392.26
Rs 485303.81Rs 5392.26
Rs 26932.20
60 tablet
Free AirMail shipping Hot
Rs 5541.97
Rs 332518.27Rs 5541.97
Rs 8972.41
30 tablet
Free AirMail shipping Hot
Rs 5691.51
Rs 170745.34Rs 5691.51
Package Per pill Price Savings Order
90 tablet
Free AirMail shipping Hot
Rs 6440.79
Rs 579671.35Rs 6440.79
Rs 26932.20
60 tablet
Free AirMail shipping Hot
Rs 6590.50
Rs 395429.96Rs 6590.50
Rs 8972.41
30 tablet
Free AirMail shipping Hot
Rs 6740.04
Rs 202201.18Rs 6740.04
Rybelsus

Brand(s)

Manufacturer

  • Novo Nordisc India Pvt. Ltd

Disease(s)

  • Type 2 Diabetes Mellitus / High Blood Sugar

Rybelsus® tablets

What is Rybelsus?

Rybelsus tablets (semaglutide) is a prescription medicine used in adults with type 2 diabetes mellitus to decrease blood sugar levels. Rybelsus can be prescribed when other diabetes medicines have been tried without success, and should be used together with diet and exercise.

Rybelsus tablets work to lower blood sugar (glucose) levels by increasing how much insulin is released and decreasing glucagon secretion. This medicine also may slow gastric emptying after eating. Rybelsus is from the class of medicines called GLP-1 receptor agonists.
Rybelsus is not for treating type 1 diabetes.
Rybelsus was first approved by the FDA on September 20, 2019.

Warnings

You should not use Rybelsus if you have multiple endocrine neoplasia type 2 (tumors in your glands), a personal or family history of medullary thyroid cancer, insulin-dependent diabetes, or diabetic ketoacidosis.
Call your doctor at once if you have signs of a thyroid tumor, such as swelling or a lump in your neck, trouble swallowing, a hoarse voice, or shortness of breath.